Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 1/2020

01-01-2020 | Fluorescence in Situ Hybridization | Images

Auer Rod-Like Inclusions in Light Chain Myeloma: A Rare Morphological Feature

Authors: Dia Mansukhani, Balkrishna Padate, Kalyani Bapat, Nazreen Desai, Shanaz Khodaiji

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 1/2020

Login to get access

Excerpt

A 72 year old male presented with persisting joint pains. On investigations he was found to have hemoglobin of 110 g/l, hypercalcemia (40 mg/dl), rising creatinine levels (2.5 mg/dl) and hypoalbuminemia. The serum protein was 5.2 g/dl and albumin was 2.8 g/dl. Serum and immunofixation electrophoresis did not reveal a monoclonal component. Beta-2 microglobulin was markedly elevated (6519 ng/ml). …
Literature
1.
go back to reference Noujaim JC, D’Angelo G (2013) Auer rod-like inclusions in κ light chain myeloma. Blood 122(17):2932CrossRef Noujaim JC, D’Angelo G (2013) Auer rod-like inclusions in κ light chain myeloma. Blood 122(17):2932CrossRef
2.
go back to reference Tejwani N, Tyagi S, Dass J (2017) Multiple Auer rod like inclusions in multiple myeloma. Indian J Hematol Blood Transfus 33(1):121–122CrossRef Tejwani N, Tyagi S, Dass J (2017) Multiple Auer rod like inclusions in multiple myeloma. Indian J Hematol Blood Transfus 33(1):121–122CrossRef
Metadata
Title
Auer Rod-Like Inclusions in Light Chain Myeloma: A Rare Morphological Feature
Authors
Dia Mansukhani
Balkrishna Padate
Kalyani Bapat
Nazreen Desai
Shanaz Khodaiji
Publication date
01-01-2020
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 1/2020
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-019-01157-y

Other articles of this Issue 1/2020

Indian Journal of Hematology and Blood Transfusion 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine